Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Priority Review's Luster Dims In "Safety First Era" But Retains Value - Parexel

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Sponsors of the most innovative new drugs should not be deterred by the apparent reversals of fortune in the last year for NDAs with priority review status, the consulting firm Parexel concludes in a new report.
Advertisement

Related Content

Has FDA Reached A "New Normal"? Parexel Thinks Lower Review Metrics May Be Here To Stay, Though FDA Hopes To Improve
Has FDA Reached A "New Normal"? Parexel Thinks Lower Review Metrics May Be Here To Stay, Though FDA Hopes To Improve
Has FDA Reached A "New Normal"? Parexel Thinks Lower Review Metrics May Be Here To Stay, Though FDA Hopes To Improve
The Good Old Days: FDA's Jenkins Instructs Reviewers To Meet Original User Fee Review Time Standard
Industry Wants More Transparency From Agency On REMS Determinations
Sponsors Can Expect REMS Discussions As Early As Phase II, FDA Says
CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class
FDA Says New GRMPs Will Shift Drug Review Workload To Earlier In Cycle
Early Meetings Aid First-Cycle Approval If Sponsors Act, Consultants Tell FDA
Key To First-Cycle Approval Is To Meet Early And Often, Consultants Tell FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS004241

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel